Captor Therapeutics S.A. Market Cap ($80.35 Million)
Market Cap & Net Worth: Captor Therapeutics S.A. (CTX)
Captor Therapeutics S.A. market cap. Captor Therapeutics S.A. (WAR:CTX) has a market capitalization of $80.35 Million (zł291.96 Million) as of November 1, 2026. Listed on the WAR stock exchange, this Poland-based company holds position #19851 globally and #160 in its home market, demonstrating a -8.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Captor Therapeutics S.A.'s stock price zł53.00 by its total outstanding shares 5508709 (5.51 Million). Also see Captor Therapeutics S.A. cash conversion from operations for how efficiently the company converts equity into cash flow.
Captor Therapeutics S.A. Market Cap History (2021–2026)
Captor Therapeutics S.A. market cap history from 2021 to 2026. Data shows change from $272.59 Million to $80.35 Million (-19.16% CAGR). Check Captor Therapeutics S.A. stock price for real-time trading data and today's change.
Captor Therapeutics S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Captor Therapeutics S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Captor Therapeutics S.A. (CTX) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.05x
Captor Therapeutics S.A.'s market cap is 4.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $272.59 Million | $3.99 Million | -$32.57 Million | 68.39x | N/A |
| 2022 | $242.57 Million | $9.16 Million | -$35.89 Million | 26.49x | N/A |
| 2023 | $150.09 Million | $13.20 Million | -$70.58 Million | 11.37x | N/A |
| 2024 | $64.13 Million | $15.82 Million | -$38.43 Million | 4.05x | N/A |
Competitor Companies of CTX by Market Capitalization
Companies near Captor Therapeutics S.A. in the global market cap rankings as of November 1, 2026. Also see Captor Therapeutics S.A. assets under control for a full breakdown of the balance sheet.
Key companies related to Captor Therapeutics S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Captor Therapeutics S.A. (2021–2026)
Market capitalization of Captor Therapeutics S.A. from 2021 to today. Between 2021 and today, Captor Therapeutics S.A.'s market cap moved from $272.59 Million to $ 80.35 Million, with a yearly change of -19.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | zł80.35 Million | -26.39% |
| 2025 | zł109.16 Million | +70.21% |
| 2024 | zł64.13 Million | -57.27% |
| 2023 | zł150.09 Million | -38.12% |
| 2022 | zł242.57 Million | -11.01% |
| 2021 | zł272.59 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Captor Therapeutics S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $80.35 Million USD |
| MoneyControl | $80.35 Million USD |
| MarketWatch | $80.35 Million USD |
| marketcap.company | $80.35 Million USD |
| Reuters | $80.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Captor Therapeutics S.A.
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. … Read more